DREAMM-8: Key study in the development of BCMA therapy up to DREAMM-14

The DREAMM-8 data presented at this year’s ASCO provided robust evidence of the efficacy and tolerability of the BPd combination (belantamab mafodotin, pomalidomide and dexamethasone) for the treatment of recurrent and refractory multiple myeloma (RRMM) with HRCA (high-risk cytogenetics). BPd, which offers a viable alternative especially for patients with HRCA for whom cell therapies are not suitable, could establish itself as a second-line therapy in Switzerland in the medium term following its recent approval by Swissmedic – even if DREAMM-14 , in which the dosage itself is being studied for the first time, could offer an optimized benefit-risk profile for ocular side effects in RRMM patients.